Acaster Lloyd Consulting Ltd, 8th Floor, Lacon House, 84 Theobalds Road, London, WC1X 8NL, UK.
Pfizer Inc, New York, NY, USA.
Qual Life Res. 2024 Jun;33(6):1581-1592. doi: 10.1007/s11136-024-03645-9. Epub 2024 Mar 29.
Alopecia areata (AA) is an autoimmune-mediated inflammatory dermatological disease characterised by non-scarring hair loss affecting the scalp and sometimes other hair-bearing sites. This study aimed to elicit health state utility values (HSUVs) from the UK general population for AA using time trade off (TTO) interviews.
Vignette descriptions of health states defined by the extent of hair loss were developed (as well as one describing caregiver burden). These were developed using data from standardised patient reported outcome (PRO) measures, a literature review and qualitative interviews. Health states were defined based on the severity of alopecia tool (SALT), which assesses extensiveness of scalp hair loss. HSUVs were then elicited for each health state in TTO interviews with the UK public.
One caregiver and five patient health states were developed based on the literature review findings, clinical trial PRO (Hospital Anxiety and Depression Scale and Alopecia Areata Patient Priority Outcomes Questionnaire) data and qualitative interviews with patients (N = 11), clinical experts (N = 4) and caregivers of adolescents with AA (N = 10). These data showed a more severe impact among patients with more extensive hair loss. One hundred and twenty participants evaluated the vignettes in TTO interviews. Patient HSUVs ranged from 0.502 for the most extensive hair loss health state (SALT 50-100 + eyebrow and eyelash loss) to 0.919 (SALT 0-10) for the mildest health state. The caregiver HSUV was 0.882.
Quantitative and qualitative data sources were used to develop and validate vignettes describing different AA health states. Patient and caregiver HSUVs demonstrate a large impact associated with AA, especially for states defined by more extensive hair loss.
斑秃(AA)是一种自身免疫介导的炎症性皮肤病,表现为非瘢痕性脱发,影响头皮,有时还影响其他毛发部位。本研究旨在通过时间权衡(TTO)访谈,从英国普通人群中获得斑秃的健康状态效用值(HSUVs)。
根据脱发程度开发了健康状态的描述性情节(还有一个描述照顾者负担的情节)。这些情节是使用标准化患者报告结果(PRO)测量、文献回顾和定性访谈中的数据开发的。健康状态是根据严重程度评估脱发工具(SALT)定义的,该工具评估头皮脱发的广泛性。然后,在英国公众的 TTO 访谈中,对每个健康状态进行 HSUV 评估。
根据文献综述结果、临床试验 PRO(医院焦虑和抑郁量表和斑秃患者优先结局问卷)数据以及与患者(N=11)、临床专家(N=4)和青少年斑秃患者的照顾者(N=10)的定性访谈,开发了一个照顾者和五个患者健康状态。这些数据表明,脱发越广泛,患者的影响越严重。120 名参与者在 TTO 访谈中评估了描述性情节。患者 HSUVs 范围从最广泛的脱发健康状态(SALT 50-100+眉毛和睫毛缺失)的 0.502 到最轻微健康状态(SALT 0-10)的 0.919。照顾者的 HSUV 为 0.882。
使用定量和定性数据源开发和验证了描述不同斑秃健康状态的描述性情节。患者和照顾者的 HSUVs 表明斑秃的影响很大,特别是对于由更广泛的脱发定义的状态。